Old HIV drug repurposed to flush out hidden virus in new pilot trial
NCT ID NCT06823596
First seen Jan 09, 2026
Summary
This pilot study tests whether adding the HIV drug efavirenz to a person's current antiretroviral therapy (ART) can kill cells that harbor hidden HIV. About 26 adults with HIV who have low but detectable virus levels despite good adherence will take efavirenz for 8 weeks. The goal is to see if this approach can reduce or eliminate that residual viremia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Maple Leaf Medical Clinic
RECRUITINGToronto, Ontario, M5G 1K2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Unity Health Toronto -St. Michael's Hospital
RECRUITINGToronto, Ontario, M5B 1W8, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Efavirenz (an HIV drug also known as Sustiva)
What this could lead to
If it works, this could point toward a way to reduce the hidden HIV reservoir and lower persistent viremia, potentially improving long-term health.
What could go wrong
This is a very small, early pilot study with only 26 participants. The effect may be modest or not work at all, and efavirenz can cause side effects like dizziness or sleep problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.